pharmaphorum November 22, 2021
Phil Taylor

On the heels of a late-stage clinical trial failure, Vifor Pharma has moved to bolster its pipeline by acquiring Spain’s Sanifit and fell Swiss biotech Inositec for a combined value of €225 million (around $254 million) upfront.

The deals mean Glattbrugg-based Vifor claims a clinical-stage drug for patients with complications of end-stage chronic kidney disease (CKD), which has been taken into phase 3 by Sanifit, as well as an Inositec compound which is set to start clinical testing shortly.

The Swiss group is paying €205 million upfront for Sanifit and SNF472, billed as a first-in-class, intravenous inhibitor of vascular calcification a condition in which minerals are deposited in the arteries or veins that is sometimes associated with atherosclerosis.

In severe...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
Walgreens Suffers $6 Billion Loss As VillageMD Clinic Investment Sours
Covid’s scientific silver lining: A chance to watch the human immune system respond in real time
How GLP-1’s moved from research labs to national TV
Understanding the politics of drug pricing in the United States
Opinion: Oprah kicked off a national conversation on obesity and GLP-1 drugs. Let’s have it

Share This Article